BACKGROUND & AIMS: Sorafenib, a multi-kinase inhibitor with anti-angiogenic activity, was
recently approved for the treatment of advanced hepatocellular carcinoma (HCC) …

Purpose Sorafenib improves overall survival and time to progression of advanced
hepatocellular (aHCC) patients such as demonstrated in 2 phase III trials. However, aHCC …

AIM: To evaluate the clinical efficacy and safety of epirubicin, cisplatin, and 5-FU
combination chemotherapy for the sorafenib-refractory metastatic hepatocellular carcinoma …

Until now, no effective systemic treatment options have been available for patients with
unresectable advanced hepatocellular carcinoma (HCC). In the Sorafenib Hepatocellular …

Purpose To determine the antitumor efficacy and tolerability of combination temozolomide
(TMZ) and veliparib (ABT-888) in patients with advanced, sorafenib-refractory hepatocellular …

Sorafenib (Nexavar®) is an orally active multikinase inhibitor that is approved in the EU for
the treatment of hepatocellular carcinoma. Monotherapy with sorafenib prolongs overall …

Background Hepatocellular carcinoma is the fifth most common cancer worldwide and the
third most common cause of cancer mortality. Advanced HCC is a distinct disease entity with …

The only approved systemic therapy for patients with advanced hepatocellular carcinoma
(HCC) till now is sorafenib. A preliminary study suggested that capecitabine, an oral …

Background Sorafenib remains one major first-line therapeutic options for advanced
hepatocellular carcinoma (aHCC), with modest efficacy. We investigated the addition of …

Purpose Sorafenib provides a survival benefit for patients with advanced hepatocellular
carcinoma (HCC). However, there has been little experience with it in Japan. This study …